Language: BG BG
← Back to results
Recruiting NCT07143669

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

Conditions: Clonal Mast Cell Disease KIT D816V Mutation Suspected KITD816V Mutated Clonal Mast Cell Disease

Sponsor: Blueprint Medicines Corporation

trial.available_in: БГ
Overview
This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.
Who can participate
Key Inclusion Criteria: * Cohort 1 participants must meet inclusion criteria for either SMAC-A or SMAC-B: 1\. SMAC-A * Documented anaphylaxis due to Hymenoptera venom with cardiovascular symptoms or * Documented anaphylaxis without known trigger(s) or allergen(s) warranting hospitalization, emergency room visit, and/or epinephrine with cardiovascular symptoms 2. SMAC-B * Episodic or recurrent signs and symptoms consistent with mast cell activation without known triggers or allergens in at least 2 of the following organ systems: skin, respiratory/naso-ocular, gastrointestinal tract, or cardiovascular. * Any clinical response on one or more optimally dosed therapies intended to mitigate mast cell mediators, as determined by the Investigator. * Cohort 2 participants must have confirmed, known diagnosis of 1 of the following criteria: 1. Either hypermobile Ehlers-Danlos syndrome or documented history of hypermobility spectrum disorder. 2. Postural orthostatic tachycardia syndrome with one or more systemic symptoms. 3. Early onset (≤50 years old) osteoporosis or osteopenia. * Cohort 3 participants must have documented diagnosis of 1 of the following, according to World Health Organization 5th edition criteria: chronic myelomonocytic leukemia or myelodysplastic syndrome/myeloproliferative neoplasm not otherwise specified. Key Exclusion Criteria: * Participants previously diagnosed with any of the following: 1. Monoclonal mast cell activation syndrome with a known KIT mutation 2. Cutaneous mastocytosis only (that is, no documentation of systemic mast cell disease via bone marrow biopsy) 3. Any subtype of systemic mastocytosis 4. Mast cell sarcoma * Cohort 2 only: Osteopenia or osteoporosis attributed to known genetic, endocrine, nutritional, or other medical conditions. Note: Additional protocol-defined criteria apply.
Interventions
Screening
OTHER
Locations 17
United States (17)
Emory University
Atlanta , Georgia
AllerVie Clinical Research
Birmingham , Alabama
O'Neal Comprehensive Cancer Center at the UAB
Birmingham , Alabama
The University of North Carolina at Chapel Hill
Chapel Hill , North Carolina
AIR Care
Dallas , Texas
AllerVie Health
Glenn Dale , Maryland
Somnos Clinical Research
Lincoln , Nebraska
Tulane University School of Medicine
New Orleans , Louisiana
Mount Sinai Hospital
New York , New York
Midwest Allergy Sinus Asthma
Normal , Illinois
Allergy, Asthma & Clinical Research Center
Oklahoma City , Oklahoma
Allergy & Clinical Immunology Associates
Pittsburgh , Pennsylvania
Kaiser Permanente San Diego
San Diego , California
Barnes-Jewish West County Hospital
St Louis , Missouri
Allergy, Asthma, & Immunology Associates of Tampa Bay
Tampa , Florida
Allergy & Asthma Clinical Research of the Bay Area
Walnut Creek , California
Care Access Research
Warwick , Rhode Island
Technical details
Status
Recruiting
Study type
OBSERVATIONAL
Sex
Male and female
Minimum age
18 Years
Healthy volunteers
No
Start date
17.10.2025
Completion date
31.10.2028
Registry ID
NCT07143669
Source
clinicaltrials.gov
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.